NeuroOne Medical Technologies (Nasdaq:NMTC) announced today that it received a patent for drug delivery with neural probe devices.
The United States Patent and Trademark Office (USPTO) issued the patent titled “Agent-Delivering Neural Probe Devices and Related Systems and Methods.” It covers novel electrodes that can operate as a standard neural electrode that delivers a treatment agent to a target area of the brain.
A step into the drug delivery space would mark further progress for NeuroOne, which develops thin-film electrode technologies.
The company already has a patent portfolio that includes both neural and spinal cord electrodes. Their unique structures optimize the functionality and minimized profile of those electrodes.